Your session is about to expire
← Back to Search
Monoclonal Antibodies
Eptinezumab for Migraine
Phase 4
Waitlist Available
Research Sponsored by H. Lundbeck A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Participant has ≥8 migraine days per month for each month within the past 3 months prior to the Screening Visit
Participant has documented evidence of recent inadequate response to either one anti-CGRP monoclonal antibody (mAb) (other than eptinezumab) or one gepant, indicated and used for migraine prevention
Must not have
Participant has previously had an inadequate response to more than one CGRP-targeting therapy (anti-CGRP mAb or gepants) indicated for migraine prevention
Participant has taken more than 10 tablets of ubrogepant or more than 8 tablets of rimegepant per month as an acute migraine medication in the 1 month prior to the screening visit and during the 4-week baseline period
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial aims to see if eptinezumab can help improve migraine symptoms and quality of life in people who have not seen enough improvement with other migraine treatments that target CGRP. "This trial
Who is the study for?
This trial is for individuals who suffer from migraines and haven't found relief with previous anti-CGRP medications. Specific criteria to join or reasons that might disqualify someone are not provided.
What is being tested?
The study is testing Eptinezumab, a medication aimed at improving symptoms and life quality in migraine sufferers who didn't respond well to prior CGRP-targeting treatments.
What are the potential side effects?
Potential side effects of Eptinezumab aren't listed here, but common ones for similar drugs include reactions at the injection site, fatigue, nausea, and allergic reactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have had 8 or more migraine days each month for the last 3 months.
Select...
I have tried a migraine prevention medication without success.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have tried more than one CGRP-targeting therapy for migraine prevention without success.
Select...
I have taken more than 10 ubrogepant or more than 8 rimegepant tablets for migraines in the last month.
Select...
I have been treated with eptinezumab before.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Side effects data
From 2020 Phase 3 trial • 485 Patients • NCT041520832%
Hypersensitivity
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Eptinezumab
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
1Treatment groups
Experimental Treatment
Group I: EptinezumabExperimental Treatment1 Intervention
Participants will receive eptinezumab at Baseline (Day 1) and Week 12
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Eptinezumab
2021
Completed Phase 3
~2200
Find a Location
Who is running the clinical trial?
H. Lundbeck A/SLead Sponsor
331 Previous Clinical Trials
78,057 Total Patients Enrolled
15 Trials studying Migraine
4,876 Patients Enrolled for Migraine